603658 安图生物
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,207,1044.70%4,443,6564,441,6273,765,9172,978,132
减:营业总成本1,583,2471.73%3,214,9603,278,3892,832,0952,193,102
    其中:营业成本764,394-0.25%1,552,2451,783,6571,525,6281,198,723
               财务费用3,812-1,018.60%8,788(2,041)14,58920,863
               资产减值损失(7,323)-65.44%(32,692)(35,777)(619)(1,664)
公允价值变动收益7,035--580--3394
投资收益38,095-26.38%129,381118,585108,34649,888
    其中:对联营企业和合营企业的投资收益(2,846)94.30%(3,369)2,000764,704
营业利润689,10013.72%1,365,7481,296,3821,076,152856,366
利润总额687,18612.89%1,362,5441,293,7151,065,549844,533
减:所得税费用60,20812.74%138,413105,03385,69387,442
净利润626,97712.91%1,224,1311,188,682979,856757,091
减:非控股权益7,464-20.84%6,69221,2456,1939,297
股东净利润619,51313.49%1,217,4391,167,437973,663747,794

市场价值指针
每股收益 (元) *1.09015.96%2.1002.0001.6601.340
每股派息 (元) *----1.0520.8000.7200.850
每股净资产 (元) *14.1345.37%14.55913.27512.41214.363
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容